Compositions and methods of treating cancer with tannin complexes

A method of treating a cancer sensitive to hydrolyzable tannins in a patient comprising administering to a patient in need thereof an effective amount of a composition comprising hydrolyzable tannins where the cancer is selected from the group consisting of nasal cavity, paranasal sinus, nasopharynx, oral cavity and oropharynx squamous cell carcinomas and adenocarcinomas;

• oral lymphomas;
• adenoid cystic carcinoma;
• paragangliomas;
• squamous cell carcinoma, adenocarcinoma, large cell (undifferentiated) carcinoma, and small cell carcinoma of the lung;
• mediastinal thymomas, lymphomas and neurogenic carcinomas;
• squamous cell carcinoma and adenocarcinoma of the esophagus;
• adenocarcinoma of the stomach;
• ductal adenocarcinoma, mucinous cystadenocarcinoma, acinar cell carcinoma, unclassified large cell carcinoma, small cell carcinoma, and pancreatoblastoma of the pancreas;
• hepatocellular carcinoma, hepatoblastoma, cholangiocarcinoma, cholangiocellular carcinoma, cystadenocarcinoma, squamous cell carcinoma, angiosarcoma, hemangioendothelioma, leiomyosarcoma, malignant schwannoma, fibrosarcoma, malignant fibrous histiocytoma, lymphoma, osteosarcoma, rhabdomyosarcoma and mesenchymal sarcoma of the liver;
• adenosarcoma, squamous cell carcinoma, adenosquamous carcinoma, oat cell carcinoma (small cell), carcinosarcoma, malignant lymphoma, malignant melanoma, rhabdomyosarcoma, fibrous histiocytoma, and angiosarcoma of the gallbladder;
• adenocarcinoma, fibrosarcoma, leiomyosarcoma, liposarcoma, angiosarcoma, lymphangiosarcoma, lymphoma, and neurofibrosarcoma of the small bowel;
• adenocarcinoma, mucinous adenocarcinoma, signet-ring cell adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, undifferentiated carcinoma, unclassified carcinoma, argentaffin carcinoid tumor, nonargentaffin carcinoid tumor, composite carcinoid tumor, and leiomyosarcoma of the large intestine;
• squamous cell carcinoma, transitional (cloacogenic) carcinoma, adenocarcinoma, papillary villous carcinoma, and mucinous adenocarcinoma of the anus;
• renal clear cell, granular cell and sarcomatoid carcinoma;
• nephroblastoma;
• transitional cell carcinoma of the ureter;
• carcinoma of the bladder;
• adenocarcinoma of the prostate;
• squamous cell carcinoma and adenocarcinoma of the cervix;
• adenocarcinoma, cystadenocarcinoma, carcinoma, and adenofibroma, cystadenofibroma, sarcoma, and adenoacanthoma of the ovary;
• papillary, follicular, and medullary carcinoma of the thyroid;
• adenoma and carcinoma of the parathyroid;
• adenoma and carcinoma of the adrenal cortex;
• fibrosarcoma, and fibrous histiocytoma, liposarcoma, squamous cell carcinoma, and sarcoma of soft tissues;
• leiomyosarcoma, and rhabdomyosarcoma of muscle tissues;
• osteogenic sarcoma, fibrosarcoma, fibrous histiocytoma and chondrosarcoma of bone;
• angiosarcoma, lymphangiosarcoma, and Kaposi's sarcoma;
• malignant glomus tumor and hemangiopericytoma;
• synovial sarcoma and giant cell tumor of the tendon sheath;
• malignant peripheral nerve sheath tumor, neurofibrosarcoma, malignant triton tumor, malignant glandular schwannoma, epithelioid schwannoma, malignant granular cell tumor, nerve clear cell sarcoma, and malignant paraganglioma;
• chondrosarcoma and osteosarcoma;
• malignant mesencymoma;
• Hodgkin's and non-Hodgkin's lymphoma;
• cutaneous T-cell lymphoma;
• Burkitt's lymphoma;
• primary nervous system lymphoma;
• acute myelocytic, acute lymphoblastic, chronic myelocytic, chronic lymphoblasfic, chronic myelogenous, acute myelogenous, acute promyelocytic, acute nonlymphocytic, acute monocytic, and acute myelocytic leukemia;
• retinoblastoma;
• malignant melanoma of the choroid;
• macroglobulinemia;
• heavy chain disease;
• and multiple myeloma.